Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained an $85 price target.

April 25, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Apellis Pharmaceuticals and maintained an $85 price target.
The reiteration of a Buy rating and maintenance of an $85 price target by a reputable analyst like Joseph Stringer from Needham is likely to instill confidence among investors and could positively influence Apellis Pharmaceuticals' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100